Journal of Clinical Oncology (JCO) Podcast

The JCO Podcast hosted by Dr. Shannon Westin features discussions of new and noteworthy results publ

Episodes

Total: 418

Though opioid abuse is clearly an issue for cancer patients post-surgery, many other potential facto

The paper examines the cost-effectiveness of schedules of bone-modifying agents in patients with bre

In this randomized trial, momelotinib was non-inferior to ruxolitinib for spleen response but was le

A Danish population based study of adults with acute myeloid leukemia is described, and the potentia

With a large database analysis, the authors found an increase in hospice use among older patients wi

T-cell therapies targeting viral diseases have evolved from a patient-specific therapy, targeting a

This podcast examines the growing evidence to support the link between risk factors for cardiovascul

Normalization of PET-CT is a strong predictor   for progression free survival (PFS) and overall surv

Randomization to different methotrexate and steroid treatment strategies was not related to neuropsy

This podcast summarizes the study finding and discuss the clinical and policy implication of an arti

In a unique approach to subsequent malignancy research, Teepen and colleagues report on subsequent s

The SWORD study is one of the first randomized controlled trials targeting fear of cancer recurrence

This podcast discusses the role of consolidation stem cell transplantation in patients with double-h

This podcast summarizes and discusses the findings from a study by Guy and colleagues about the econ

This randomized controlled trial shows that Treatment Summary Survivorship Plans increase physician

This podcast discusses the association between smoking and risk of death from pancreatic cancer.

Patients who had autologous reconstruction had higher satisfaction with breasts and well-being than

This podcast describes the results and implications of the article published by Landier et al, descr

By Amanda Psyrri  The findings of KEYNOTE-055 are summarized and compared to other immunotherapy stu

Podcast re: 'Three-year Follow-up of an Alectinib Phase 1/2 Study in ALK-Positive Non-Small-Cell Lun